Steglujan

(ertugliflozin/sitagliptin) MSD

Composition:

• Available in tablet with each contains 15 mg ertugliflozin (as ertugliflozin L-pyroglutamic acid) and 100 mg sitagliptin (as sitagliptin phosphate monohydrate)

Indication:

• As an adjunct to diet and exercise to improve glycaemic control in adults aged 18 years and older with type 2 diabetes mellitus:
• when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control
• in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets

Drug information including formulation, indication, administration and/or presentation updated, registered or launched in Hong Kong within one year prior to the date written is regarded as new in The Pace.

The information in The Pace is provided as a courtesy service to our readers and is intended for medical professional reference only. Please peruse the latest local prescription information prior to prescription.